Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Removing classification of prescription only medicine from injectable vitamin B12
| Agent | FDA Approval | Mean Weight Loss (RCT) | Route | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Yes (2021) | 14.9% at 68 weeks (STEP-1, N=1,961) [9] | Subcutaneous weekly | | Tirzepatide 15 mg (Zepbound) | Yes (2023) | 20.9% at 72 weeks (SURMOUNT-1, N=2,539) [11] | Subcutaneous weekly | | AOD-9604 1 mg oral | No | ~2.8 kg at 12 weeks (Phase IIb, N=300 approx.) [1] | Oral (not currently compounded) | The weight-loss magnitude from the single Phase IIb AOD-9604 trial is substantially smaller than what STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) demonstrated in larger, longer trials
After doing so, update the Telehealth prescribing provider so that everyone involved in your care is informed
People seeking respiratory support NAC's longest history of use outside the hospital setting is in respiratory health
US$ 27.99
US$ 24.67
US$ 27.76
US$ 27.34
US$ 28.95
